The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Possibile role of vascular endothelial growth factor (VEGF) levels in immunodepleted plasma of metastatic colorectal cancer (mCRC) patients (pts) treated with a biweekly administration of capecitabine plus oxaliplatin (XELOX-2) plus bevacizumab: Preliminary results.
N. Silvestris
No relevant relationships to disclose
A. Azzariti
No relevant relationships to disclose
L. Porcelli
No relevant relationships to disclose
A. E. Quatrale
No relevant relationships to disclose
A. Paradiso
No relevant relationships to disclose
G. Colucci
No relevant relationships to disclose